Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer
JAMA Network Open · 10.04.2026 · 9 (4) · e264901
DOI: 10.1001/jamanetworkopen.2026.4901 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 10.04.2026. Verfasst von Meghna S Trivedi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bridged-Ring Compounds, Neoplasms, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Taxane-induced peripheral neuropathy (TIPN) affects quality of life and ability to complete cancer treatment and has limited effective interventions for prevention and treatment.
Objective
To develop and validate a TIPN risk prediction model. Design, Setting, and Participants SWOG S1714 was a prospective observational cohort study conducted at sites in the National Cancer Institute National Community Oncology Research Program between March 1, 2019, and November 15, 2021, with 3 years of follow-up. The study included evaluable participants 18 years or older with stage I to III lung, breast, or ovarian, fallopian tube, or primary peritoneal cancer who were starting taxane-based treatment. Statistical analysis was conducted from December 2023 to June 2024. Exposures Taxane-based regimens including paclitaxel or docetaxel. Main Outcomes and Measures The primary end point was occurrence of TIPN by 24 weeks. TIPN was assessed using the patient-reported European Organization of Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-item scale (CIPN-20) at baseline and weeks 4, 8, 12, and 24. Occurrence of TIPN was defined as an increase of 8 points or more over baseline in the CIPN-20 sensory subscale score. With a 60% random sample of evaluable participants, best-subset selection using logistic regression and k -fold cross-validation identified a best model based on demographic factors, baseline comorbid conditions, and treatment factors. Adverse risk factors were summed, generating a score, split at the median and tested in the remaining 40% of evaluable participants. The target difference was 12% between high-risk vs low-risk groups.
Results
A total of 1336 participants enrolled in S1714. Of 1278 evaluable participants (median age, 55.0 years [range, 23.0-84.0 years]; 1264 women [98.9%]; 1164 with breast cancer [91.1%]), 804 (62.9%) experienced TIPN by week 24. Using the training set of 768 participants, a risk prediction model for TIPN was developed that included 5 adverse risk factors: receipt of paclitaxel; stage II or III disease; planned taxane duration of more than 12 weeks; diabetes, autoimmune disease, moderate kidney disease, or a neurologic condition; and self-identified race and ethnicity (Black, Hispanic, Native American, Pacific Islander, multiple races, or unknown race or ethnicity). In the test set of 510 participants, TIPN was more common in high-risk (235 of 345 [68.1%]) vs low-risk (84 of 165 [50.9%]) groups (absolute difference, 17.2%), exceeding the 12% target. Conclusions and Relevance In this cohort study of participants with early-stage cancer receiving a taxane regimen, a set of baseline risk factors stratified TIPN risk. A risk prediction model may guide treatment decision-making, symptom monitoring, and enrollment in interventional trials for TIPN prevention and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
- SWOG Cancer Research Network Statistics and Data Management Center, Seattle, Washington.
- Fred Hutch Cancer Center, Seattle, Washington.
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor.
- Peripheral Neuropathy Center, Columbia University Medical Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Trivedi, M. S., Unger, J. M., Henry, N. L., Darke, A. K., Hertz, D. L., Brannagan, T. H., Reyes, S. J., Schneider, B. P., Irvin, W. J., Hathaway, A. R., Vander Woude, A. C., Gudena, V. K., Cabrera-Galeana, P., Orsted, M., LeBlanc, M., Fisch, M. J., & Hershman, D. L. (2026). Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer. JAMA Network Open, 9(4), e264901. https://doi.org/10.1001/jamanetworkopen.2026.4901
Vancouver
Trivedi MS, Unger JM, Henry NL, Darke AK, Hertz DL, Brannagan TH, et al. Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer. JAMA Network Open. 2026;9(4):e264901. doi:10.1001/jamanetworkopen.2026.4901
BibTeX
@article{Trivedi2026,
author = {Trivedi, Meghna S and Unger, Joseph M and Henry, N Lynn and Darke, Amy K and Hertz, Daniel L and Brannagan, Thomas H and Reyes, Stephanie J and Schneider, Bryan P and Irvin, William J and Hathaway, Amanda R and Vander Woude, Amy C and Gudena, Vinay K and Cabrera-Galeana, Paula and Orsted, Mary and LeBlanc, Michael and Fisch, Michael J and Hershman, Dawn L},
title = {Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {4},
pages = {e264901},
doi = {10.1001/jamanetworkopen.2026.4901}
}
EUVIMED